- Home
- BBU vs MIRM Comparison
BBU vs MIRM Comparison
Compare BBU & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBU
- MIRM
- Stock Information
- Founded
- BBU 2016
- MIRM 2018
- Country
- BBU Bermuda
- MIRM United States
- Employees
- BBU N/A
- MIRM N/A
- Industry
- BBU Engineering & Construction
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- BBU Consumer Discretionary
- MIRM Health Care
- Exchange
- BBU Nasdaq
- MIRM Nasdaq
- Market Cap
- BBU 2.3B
- MIRM 2.5B
- IPO Year
- BBU N/A
- MIRM 2019
- Fundamental
- Price
- BBU $25.55
- MIRM $51.49
- Analyst Decision
- BBU Buy
- MIRM Strong Buy
- Analyst Count
- BBU 6
- MIRM 9
- Target Price
- BBU $31.33
- MIRM $66.22
- AVG Volume (30 Days)
- BBU 25.2K
- MIRM 378.4K
- Earning Date
- BBU 08-01-2025
- MIRM 08-06-2025
- Dividend Yield
- BBU 0.98%
- MIRM N/A
- EPS Growth
- BBU N/A
- MIRM N/A
- EPS
- BBU N/A
- MIRM N/A
- Revenue
- BBU $35,354,000,000.00
- MIRM $379,251,000.00
- Revenue This Year
- BBU N/A
- MIRM $35.83
- Revenue Next Year
- BBU N/A
- MIRM $16.83
- P/E Ratio
- BBU N/A
- MIRM N/A
- Revenue Growth
- BBU N/A
- MIRM 69.31
- 52 Week Low
- BBU $18.45
- MIRM $36.20
- 52 Week High
- BBU $27.47
- MIRM $54.78
- Technical
- Relative Strength Index (RSI)
- BBU 49.49
- MIRM 52.47
- Support Level
- BBU $25.13
- MIRM $51.22
- Resistance Level
- BBU $25.92
- MIRM $53.78
- Average True Range (ATR)
- BBU 0.70
- MIRM 1.61
- MACD
- BBU -0.09
- MIRM -0.27
- Stochastic Oscillator
- BBU 31.69
- MIRM 19.56
About BBU Brookfield Business Partners L.P. Limited Partnership Units
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.